Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis

Neurorehabilitation and Neural Repair

Volumn 25, Issue 7, 2011, Pages 672-679

  Phan Ba, Rémy ^a,b   Pace, Amy ^c   Calay, Philippe ^a,b   Grodent, Patrick ^a   Douchamps, Frédéric ^a   Hyde, Robert ^c   Hotermans, Christophe ^c   Delvaux, Valérie ^a,b   Hansen, Isabelle ^a,b   Moonen, Gustave ^b   Belachew, Shibeshih ^a,b  

^a MYelin Disorders REseArch TeaM ^*  (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c BIOGEN   (United States)

Author keywords

ambulation walking; disability progression; EDSS; multiple sclerosis; outcome measurement

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GAIT; HUMAN; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM WALKING DISTANCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; TEST RETEST RELIABILITY; WALKING; WALKING SPEED;

ADOLESCENT; ADULT; AGED; FEMALE; GAIT; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVER VARIATION; PSYCHOMOTOR PERFORMANCE; REPRODUCIBILITY OF RESULTS; ROC CURVE; WALKING; YOUNG ADULT;

EID: 80051519203     PISSN: 15459683     EISSN: 15526844     Source Type: Journal    
DOI: 10.1177/1545968310397204     Document Type: Article

References (18)

1. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003 ; 60: 31-36 (Pubitemid 36070640)
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
3. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 ; 122 (pt 5). 871-882 (Pubitemid 29219261)
4. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 ; 373: 732-738
5. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000 ; 54: 802-806 (Pubitemid 30111332)
6. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999 ; 5: 244-250 (Pubitemid 29405620)
7. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000 ; 6: 286-290
8. Nieuwenhuis MM, Van Tongeren H, Sorensen PS, Ravnborg M. The six spot step test: a new measurement for walking ability in multiple sclerosis. Mult Scler. 2006 ; 12: 495-500 (Pubitemid 44132591)
9. Schwid SR, Thornton CA, Pandya S, et al. Quantitative assessment of motor fatigue and strength in MS. Neurology. 1999 ; 53: 743-750 (Pubitemid 29448294)
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231 (Pubitemid 13158528)
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846 (Pubitemid 41746873)
12. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979 ; 86: 420-428
13. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. Statistician. 1983 ; 32: 307-317
14. Creange A, Serre I, Levasseur M, et al. Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler. 2007 ; 13: 220-223 (Pubitemid 46592775)
15. Lin F, Yu C, Jiang T, Li K, Chan P. Diffusion tensor tractography-based group mapping of the pyramidal tract in relapsing-remitting multiple sclerosis patients. AJNR Am J Neuroradiol. 2007 ; 28: 278-282 (Pubitemid 46281045)
16. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011 ; 18 (2). 240-245
17. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008 ; 14: 383-390 (Pubitemid 351676433)
18. Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair. 2009 ; 23: 108-116